News
-
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Zentek Announces Promising Preclinical Safety and Toxicity Results achieved by Triera Biosciences Ltd. for C19HBA
Zentek Ltd. announces successful safety and toxicity testing of C19HBA SARS-CoV-2 universal aptamer in preclinical trials, showing promising results for future human therapeutics -
COMMUNIQUÉ DE PRESSE
Zentek Announces Positive Therapeutic Results achieved by Triera Biosciences for C19HBA
Zentek Ltd.'s subsidiary Triera Biosciences completes successful testing of C19HBA aptamer as therapeutic for SARS-CoV-2, outperforming monoclonal antibody in preclinical trials. C19HBA shows potential for prophylaxis and treatment. Future clinical trials and partnerships to be pursued